Zacks Research Brokers Reduce Earnings Estimates for PCRX

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Investment analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Pacira BioSciences in a research note issued to investors on Wednesday, December 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.60 for the quarter, down from their prior estimate of $0.61. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q3 2025 earnings at $0.54 EPS and Q2 2026 earnings at $0.63 EPS.

A number of other brokerages have also weighed in on PCRX. HC Wainwright restated a “buy” rating and issued a $39.00 target price on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Pacira BioSciences in a research note on Friday, November 8th. Royal Bank of Canada lifted their target price on Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Barclays lowered their target price on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Finally, Jefferies Financial Group lifted their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Pacira BioSciences currently has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Price Performance

NASDAQ:PCRX opened at $19.86 on Friday. The firm has a market cap of $916.94 million, a PE ratio of -9.78 and a beta of 0.80. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences has a 12 month low of $11.16 and a 12 month high of $35.95. The company’s 50-day moving average price is $17.27 and its two-hundred day moving average price is $19.12.

Hedge Funds Weigh In On Pacira BioSciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. Pacer Advisors Inc. grew its holdings in shares of Pacira BioSciences by 129.4% during the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after purchasing an additional 2,799,434 shares during the last quarter. Fort Washington Investment Advisors Inc. OH acquired a new stake in shares of Pacira BioSciences during the 2nd quarter valued at $13,240,000. Assenagon Asset Management S.A. increased its holdings in Pacira BioSciences by 314.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock worth $8,324,000 after purchasing an additional 419,656 shares in the last quarter. Doma Perpetual Capital Management LLC boosted its stake in shares of Pacira BioSciences by 71.8% during the second quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock valued at $28,632,000 after purchasing an additional 418,321 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Pacira BioSciences by 269.7% in the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after buying an additional 288,662 shares during the period. Institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.